TITLE

Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer

AUTHOR(S)
Miger, Jasmine; Holmqvist, Annika; Sun, Xiao-Feng; Albertsson, Maria
PUB. DATE
March 2014
SOURCE
Medical Oncology;Mar2014, Vol. 31 Issue 3, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
94629108

 

Related Articles

  • Oral treatment is equal to intravenous for colon cancer.  // British Journal of Hospital Medicine (17508460);Aug2008, Vol. 69 Issue 8, p439 

    The article reports on the medical study that proves that patients with colon cancer treated with oral chemotherapy Xeloda (capecitabine) live just as long as those who were treated with intravenous 5-fluorouracil/folinic acid chemotherapy after surgery. The information was presented at the...

  • Sound bites.  // Gastrointestinal Nursing;Apr2010, Vol. 8 Issue 3, p14 

    The article offers various medical news briefs. The paediatric inflammatory bowel disease prevalence in China is growing. A new support group for people suffering from gastrointestinal cancer has been set up by a group of specialist nurses from Colchester General Hospital. The combination of...

  • Fluoropyrimidines: A Critical Evaluation. Brito, Rogelio A.; Medgyesy, Diana; Zukowski, Thomas H.; Royce, Melanie E; Ravandi-Kashani, Farhad; Hoff, Paulo M.; Pazdur, Richard // Oncology;1999 Supplement 1, Vol. 57, p2 

    After nearly four decades of clinical experience with the fluoropyrimidines, 5-fluorouracil (5-FU) remains an integral part of chemotherapy for colorectal cancer. A range of 5-FU treatment regimens with or without biochemical modulation are currently used and toxicity appears to be schedule...

  • Roche: strong data for Xeloda.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p4 

    Reports that studies presented at the Gastrointestinal Cancer Symposium show that a Xeloda and irinotecan combination is effective and well-tolerated as a first-line treatment of advanced colorectal cancer. Response rates; Median time to progression; Description of Xeloda as an oral prodrug of...

  • Lipid Profile in Patients with Cancer before and After Receiving Xeloda. Esfanai, Ali; Yahyavi, Shahrzad; Agamohamadzadeh, Naser; Ebrahimi, Shiva // Medical Journal of Tabriz University of Medical Sciences & Healt;Sep2015, Vol. 37 Issue 3, p12 

    Background and Objectives: Capecitabine (Xeloda) is an orally administered pro-drug of 5-fluorouraciL which is used as chemotherapeutic agent. Some studies have raised concerns about the lipid profile changes following Xeloda. In this study we examined such probable changes in patients before...

  • TELLTALE SIGNS TO LOOK OUT FOR.  // Mail on Sunday;6/23/2019, p55 

    DPD is an enzyme made by the liver. It helps the body to break down two common chemotherapy drugs - fluorouracil, or 5FU, and capecitabine, which is also known as Xeloda. These are used as a treatment for a number of different cancers, including those in the breast, bowel and stomach.

  • Xeloda: Another choice for advanced breast ca. Cerrato, Paul L. // RN;Sep98, Vol. 61 Issue 9, p92 

    Gives information on the approval of capecitabine (Xeloda) for the use by women with advanced breast cancer. How the medication should be taken; Identification of adverse effects of the drug.

  • Xeloda.  // Pharmaceutical Representative;Sep2005, Vol. 35 Issue 9, p13 

    Highlights the results of the X-ACT trial which indicate that oral treatment with Nutley, New Jersey-based Roche's Xeloda (capecitabine) may be an effective alternative to intravenous fluorouracil plus leucovorin in the post-surgical treatment of colon cancer. Adjuvant treatment with oral...

  • 'Xelox' comes with warning. A. C. // New Zealand Doctor;3/26/2008, p26 

    The article reports on the warning from oncology professor Jim Cassidy on the side effects of the Xelox chemotherapy regimen in colorectal cancer patients. The regimen combines Roche's capecitabine product Xeloda with Sanofi's oxaliplatin. Xeloda is able to shrink liver metastases. Side effects...

  • Xeloda[sup ®] in the Treatment of Metastatic Breast Cancer. Blum, Joanne L. // Oncology;1999 Supplement 1, Vol. 57, p16 

    There are few treatment options available for patients with metastatic breast cancer who have failed anthracycline- and paclitaxel-based chemotherapy. Xeloda[sup ®] (capecitabine) is a novel selectively tumoractivated[sup TM] fluoropyrimidine carbamate producing clinically active levels of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics